Kezar Life Sciences Inc (KZR) - Total Liabilities
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) has total liabilities worth $2.76 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Kezar Life Sciences Inc equity growth rate to track the company's year-over-year net asset growth rate.
Kezar Life Sciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Kezar Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Kezar Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sarawak Cable Bhd
KLSE:5170
|
Malaysia | RM466.66 Million |
|
Black Spruce Exploration Inc.
V:BARK
|
Canada | CA$2.83 Million |
|
Centaurus Energy Inc
V:CTA
|
Canada | CA$5.59 Million |
|
Capital Gearing Trust
LSE:CGT
|
UK | GBX2.47 Million |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
Indonesia | Rp569.64 Billion |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
Germany | €35.06 Million |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
USA | $121.13 Million |
|
Wingara AG Ltd
AU:WNR
|
Australia | AU$1.31 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Kezar Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kezar Life Sciences Inc (KZR) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kezar Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kezar Life Sciences Inc (2016–2025)
The table below shows the annual total liabilities of Kezar Life Sciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.57 Million | -76.32% |
| 2024-12-31 | $27.77 Million | -17.52% |
| 2023-12-31 | $33.66 Million | +13.37% |
| 2022-12-31 | $29.70 Million | +41.03% |
| 2021-12-31 | $21.06 Million | +93.82% |
| 2020-12-31 | $10.86 Million | -5.26% |
| 2019-12-31 | $11.47 Million | +94.85% |
| 2018-12-31 | $5.88 Million | -92.64% |
| 2017-12-31 | $79.91 Million | +176.96% |
| 2016-12-31 | $28.85 Million | -- |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more